| Literature DB >> 31195742 |
Mariarosaria Leporini1, Monica Rosa Loizzo2, Rosa Tundis3, Chiara La Torre4, Alessia Fazio5, Pierluigi Plastina6.
Abstract
N-Eicosapentaenoyl vanillylamine (EPVA) and N-docosahexaenoyl vanillylamine (DHVA), derived from n-3 polyunsaturated eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, were studied for their potential antioxidant and carbohydrate-hydrolysing enzyme inhibitory activities together with capsaicin and the corresponding n-3 polyunsaturated fatty acids (PUFAs). The antioxidant potential was evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) assay, β-carotene bleaching test, and ferric reducing ability power (FRAP). In the ABTS assay the following trend of potency could be observed EPVA > DHVA ≥ capsaicin. In addition, except for the FRAP test, all samples showed a greater activity than the positive controls used as reference compounds in the antioxidant assays. Both EPVA and DHVA showed half maximal inhibitory concentration (IC50) values much lower than acarbose, which was used as the reference drug in the carbohydrate-hydrolysing enzyme inhibitory activity assays. It is interesting to note that structural changes in capsaicin derivatives had higher impacts on α-glucosidase than on α-amylase inhibition. Taken together, our data suggest that both EPVA and DHVA, which are not limited in compliance-related considerations with respect to capsaicin, due to absence of pungency, could be proposed as functional ingredients for the development of products for the management of type II diabetes and border-line hyperglycaemic patients.Entities:
Keywords: PUFA; capsaicin; diabetes; fatty acid amides; vanillylamides
Year: 2019 PMID: 31195742 PMCID: PMC6616483 DOI: 10.3390/antiox8060162
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1n-3 polyunsaturated fatty acid (PUFA)-derived capsaicin analogues.
Carbohydrate-hydrolysing enzyme inhibitory activities (IC50 µM).
| Samples | α-Amylase |
| α-Glucosidase |
|
|---|---|---|---|---|
| EPVA | 33 ± 2 **** | 0.002 | 24 ± 2 **** | 0.002 |
| DHVA | 31 ± 1 **** | 0.002 | 24 ± 2 **** | 0.002 |
| Capsaicin | 27 ± 1 **** | 0.001 | 13 ± 1 **** | 0.001 |
| EPA | 267 ± 9 **** | 0.01 | 250 ± 9 **** | 0.01 |
| DHA | 209 ± 9 **** | 0.01 | 268 ± 9 **** | 0.01 |
|
| ||||
| Acarbose | 77 ± 2 | 0.004 | 54 ± 2 | 0.003 |
EPVA: N-eicosapentaenoyl vanillylamine; DHVA: N-docosahexaenoyl vanillylamine; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid. Data represent means ± S.D. (n = 3). Acarbose was used as positive control in α-amylase and α-glucosidase tests. Differences within and between groups were evaluated by one-way ANOVA followed by a multicomparison Dunnett’s test (α = 0.05): **** p < 0.0001 compared with the positive controls.
Antioxidant activities of capsaicin and its derivatives.
| Sample | DPPH Test IC50 (µM) | ABTS Test IC50 (µM) | β-Carotene Bleaching Test IC50 (µM) | FRAP Test (μM Fe(II)/g) | |
|---|---|---|---|---|---|
| 30 min | 60 min | ||||
| EPVA | 1.0 ± 0.0 **** | 0.2 ± 0.0 **** | 9 ± 1 * | 11 ± 1 * | 28 ± 2 |
| DHVA | 0.8 ± 0.0 **** | 0.3 ± 0.0 **** | 46 ± 3 **** | 56 ± 3 **** | 18 ± 2 |
| Capsaicin | 0.6 ± 0.0 **** | 0.3 ± 0.0 **** | 10 ± 1 * | 11 ± 1 * | 30 ± 3 |
| EPA | NA^ | NA^ | 74 ± 5 **** | 310 ± 10 **** | 4.8 ± 0.8 |
| DHA | NA^ | NA^ | 70 ± 4 **** | 287 ± 10 **** | 9 ± 1 |
|
| |||||
| Ascorbic acid | 23 ± 2 | 9.6 ± 0.9 | |||
| Propyl gallate | 0.4 ± 0.0 | 0.4 ± 0.0 | |||
| BHT | 63 ± 4 | ||||
BHT: butylated hydroxytoluene. Data are expressed as means ± S.D. (n = 3). NA^: Not active at maximum concentration tested (0.125 μM). Differences within and between groups were evaluated by one-way ANOVA followed by a multicomparison Dunnett’s test (α = 0.05): **** p < 0.0001, * p < 0.1 compared with the positive controls.
Figure 2Global Antioxidant Score (GAS) values of n-3 PUFA-derived capsaicin analogues.